GlassScriptPhysician profile
Geeta Gupta
NPI 1659383651
$9,093.37
in general payments reported to CMS, 2019-2025
40 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $770 · 2021: $1,294 · 2022: $1,084 · 2023: $1,218 · 2024: $2,117 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Travel and Lodging: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.04 |
| Travel and Lodging | $864.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,308.61 | 2024-2025 | Barostim Neo System |
| Boston Scientific Corporation | $1,208.22 | 2019-2025 | Watchman Flx, General - Crm_crm |
| Amgen INC. | $773.18 | 2019-2024 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $735.92 | 2019-2024 | Aveir |
| Janssen Pharmaceuticals, INC | $702.29 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.97 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $513.80 | 2019-2023 | |
| Philips North America LLC | $480.32 | 2022-2025 | (5044) Mcot, Mcot, (5050) Extended Holter |
| Novo Nordisk INC | $381.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $280.42 | 2020-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $258.32 | 2020-2024 | Verquvo |
| Corcept Therapeutics | $247.72 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $171.18 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $150.39 | 2019-2022 | |
| Silk Road Medical, INC. | $122.04 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.23 | 2020-2021 | |
| Edwards Lifesciences Corporation | $108.82 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medicomp INC | $99.03 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $98.08 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $92.32 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $71.21 | 2019-2023 | Evkeeza |
| Digirad Health, INC | $55.28 | 2022 | |
| Arbor Pharmaceuticals, INC. | $54.70 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2020-2021 | |
| Esperion Therapeutics, INC. | $49.29 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.23 | 2019-2022 | |
| Sanofi Pasteur INC. | $43.67 | 2019-2021 | |
| Heartflow, INC. | $43.52 | 2024 | |
| Glaxosmithkline, LLC. | $41.65 | 2020 | |
| Astellas Pharma US INC | $41.12 | 2020-2021 | |
| Vital Connect, INC | $35.80 | 2025 | Vitalpatch Rtm |
| Chiesi USA, INC. | $30.68 | 2024 | Juxtapid |
| Alexion Pharmaceuticals, INC. | $30.03 | 2021 | |
| Scpharmaceuticals INC. | $29.56 | 2024 | |
| Preventice Services, LLC | $28.37 | 2021 | |
| G Medical Diagnostic Services, INC. | $17.42 | 2019 | |
| Lilly USA, LLC | $16.64 | 2024 | Amyvid |
| Daiichi Sankyo INC. | $14.88 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.44 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.82 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.